Could a clogged brain drain trigger MS? new MRI study investigates
NCT ID NCT06274671
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study uses special MRI scans to check if the brain's waste-clearing system, called the glymphatic system, is not working properly in people with Clinically Isolated Syndrome (CIS), which is often the first sign of Multiple Sclerosis (MS). Researchers will compare scans from 30 people with CIS to healthy volunteers. The goal is to see if a faulty glymphatic system might contribute to inflammation and brain damage in early MS.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could show that the brain's waste-clearing system plays a role in early MS, paving the way for larger studies on new treatments.
- What could go wrong
- This is a very small pilot study (30 people) that only looks at scans, not treatments. It may not find clear differences or lead to any direct benefit for patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 30 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2024
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Group 1: Patients with a diagnosis of Clinically Isolated Syndrome Group 2: Healthy controls
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Male or female, aged 18 or over 2. Suitable physically and psychologically to undertake the assessments, as judged by the Investigator 3. Have voluntarily provided informed consent and have signed an ICF indicating that the purpose of the study has been explained and are willing and able to adhere to the study procedures described in the ICF. 4. (For CIS group): A diagnosis of CIS or MS at first presentation 5. Subjects must not have taken corticosteroids or IVIg or plasma-exchange within the 30 days prior to consent 6. Adequate vision and hearing to perform the study procedures 7. Medically healthy with no clinically significant findings on physical examination, laboratory profiles, vital signs at screening (with the exception of the signs of the condition under investigation) 8. Women of child-bearing potential must practice a medically acceptable method of birth control. Acceptable methods include oral contraceptive, contraceptive patch, long-acting injectable contraceptive, or double-barrier method (condom or intrauterine device with spermicide). 9. If on immunomodulatory medication, patients must have started it at least 30 days from screening and should not change their medication dose for the duration of the study. Exclusion Criteria: 1. Have a diagnosis of clinically definite Multiple Sclerosis according to the 2017 McDonald's Criteria (Thompson et al., 2018) 2. Have a CIS limited to the spinal cord (transverse myelitis) 3. Present psychiatric disorders or severe cognitive deficit 4. Past or present history of drug or alcohol abuse 5. Are pregnant or breastfeeding, if females of childbearing potential 6. Have any other medical, neurological, or psychiatric condition or clinically significant laboratory abnormality excluding CIS which, in the opinion of the Investigator, might preclude participation 7. Are taking benzodiazepines on a regular basis or are unable to suspend intake of benzodiazepines 8. Have received any investigational product within a time-period equal to five half-lives of the product, if known, or minimum of 60 days before consent 9. Are unable to lie down for MRI scanning 10. Have any finding on the brain MRI that would compromise subject safety or the scientific integrity of the study 11. Have implants, such as implanted cardiac pacemakers or defibrillators, insulin pumps, cochlear implants, metallic ocular foreign body, implanted neural stimulators, aneurysm clips, or other medical implants that have not been deemed safe for MRI 12. Have a history of claustrophobia 13. Have any other contraindication to MRI scanning 14. Have a relapse occurred after consent but before the MRI scan 15. It is preferable the following laboratory tests are part of the subject's medical history for differential diagnosis of clinically isolated syndrome (CIS): erythrocyte sedimentation rate (ESR), antinuclear antibody (ANA), complement (C3, C4) and anticardiolipin IgG - IgM
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Clinically isolated syndrome are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Royal Devon University Healthcare NHS Foundation Trust
Exeter, United Kingdom
-
University of Exeter
Exeter, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can pregnancy and neurological disease coexist safely? a new registry seeks answers
- Massive italian MS registry aims to unlock secrets of the disease
- Scientists hunt for harmful immune cells in MS patients
- Can ocrelizumab tame MS inflammation from the start? new study aims to find out
- MS drug in breastmilk: new study checks baby safety
- AI takes on MS: new study aims to predict disease progression